Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
Status:
Withdrawn
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The study will evaluate safety, tolerability, efficacy, pharmacokinetics, and
pharmacodynamics of 2 different doses (approved dose and lower dose) of asfotase alfa in
adult participants with pediatric-onset hypophosphatasia (HPP).